At the news
? MIXEDIMPACT 6/10 8-K filed Feb 25, 2026 at 16:08 ET
Arcus Biosciences reported Q4 and full-year 2025 financial results, highlighting strong clinical data for its drug candidate casdatifan in kidney cancer, including a median progression-free survival of 15.1 months and a 45% response rate. The company maintains a robust $1 billion cash position with runway into 2028, while R&D expenses increased to $121 million in Q4. Revenue declined slightly to $33 million from $36 million year-over-year.
- Updated data for casdatifan showed 15.1 months median PFS and 45.2% confirmed response rate in 100mg cohort
- Cash, cash equivalents and marketable securities were $1.0 billion as of December 31, 2025
- Q4 2025 revenue was $33 million, down from $36 million in Q4 2024
- Q4 2025 R&D expenses were $121 million, up from $111 million in Q4 2024
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access